These results suggest that the inhibition of AA metabolism by the 5-LOX pathway is associated with the antiproliferation activity of the mentioned drug, exhibiting clinical therapeutic value for patients with pancreatic cancer [51]. Here, ALOX5 is linked to familial pancreatic carcinoma.